Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation



Status:Active, not recruiting
Conditions:Blood Cancer, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:April 2011
End Date:July 2016

Use our guide to learn which trials are right for you!

This protocol will investigate the effectiveness of plerixafor in the up-front setting in
avoiding a second round of mobilization and whether this translates into a clinical and
economic benefit.

Peripheral blood stem cells are now considered the standard source of stem cells for
autologous stem cell transplants. Unfortunately, there is still a 20-30% chance that
inadequate numbers of stem cells will be collected, resulting in prolonged recovery of cell
counts after transplantation and increased transfusion dependence. There is also a
significant economic burden associated with remobilization and a risk that delays in
collecting sufficient numbers of stem cells can result in an increased chance of disease
recurrence prior to transplantation.

Inclusion Criteria:

- Patients with multiple myeloma or non-Hodgkin's lymphoma with a planned autologous
transplant and who are eligible for peripheral stem cell mobilization.

- Karnofsky Performance Status ≥ 70.

- Age ≥ 18

- Less than 30% involvement of marrow with disease.

Exclusion Criteria:

- > 30% marrow involvement with disease

- Age < 18.

- Pregnant women.
We found this trial at
1
site
?
mi
from
Gainesville, FL
Click here to add this to my saved trials